Open Access Open Access  Restricted Access Subscription or Fee Access

RECENT STUDIES OF DRUGS IN TUBERCULOSIS

K. Shanmugapriya, Dr.S. Kameshwaran, S. Shameem, A. Saranya, S.M. Shabariraj, K.P. Sathish

Abstract


The infectious disease tuberculosis (TB), which is brought on by a particular type of bacteria, typically affects the lungs. When infected individuals cough, sneeze, or spit, the virus is disseminated through the air. There are ways to prevent and treat tuberculosis. According to estimates, the TB pathogen has infected around a quarter of the world's population. A cough that lasts longer than three weeks, together with the possibility of phlegm or blood-tinged mucus, are signs of TB. feeling weary or worn out. a fever or sweats during the night.appetite loss. decrease of weight.having a bad overall feeling.It is crucial to comprehend how such subpopulations of M.tb are created during human infection in order to create better medication combinations that efficiently target various mycobacterial phonotypes.

Keywords


Tuberculosis, mycobacterial phonotypes, bacteria, appetite loss, blood-tinged mucus.

Full Text:

PDF

References


”Tuberculosis (TB)”who.int.Archived from the original on 30 July 2020.Retrieved 8 May 2020.

Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, et al. (December 2014). “Tuberculosis vaccines and prevention of infection”.Microbiology and Molecular Biology Reviews. 78 (4): 650–71. Doi:10.1128/MMBR. 00021- 14.

Implementing the WHO Stop TB Strategy: a handbook for national TB control programmes. Geneva: World Health Organization (WHO). 2008. P. 179. ISBN 978-92-4-154667-6.Archived from the original on 2 June 2021.Retrieved 17 September 2017.

Harris RE (2013). “Epidemiology of Tuberculosis”. Epidemiology of chronic disease: global perspectives. Burlington, MA: Jones & Bartlett Learning. P. 682.ISBN 978-0-7637-8047-0.

Lawn SD, Zumla AI (July 2011). “Tuberculosis”.Lancet. 378 (9785): 57–72. Doi:10.1016/S0140-6736(10)62173-3.Archived from the original on 27 August 2021. Retrieved 31 January 2020.

“Landmark TB Trial Identifies Shorter-Course Treatment Regimen”. CDC. NCHHSTP Media Team Centers for Disease Control and Prevention. 20 October 2020. Retrieved 27 November 2021.

KD Tripathi. Essential of medical pharmacology eighth edition 2019. 8.“Bedaquiline Fumarate”. The American Society of Health-System Pharmacists.Archived from the original on 20 December 2016.Retrieved 8 December 2016.

“Press Announcements – FDA approves first drug to treat multi-drug resistant tuberculosis”. www.fda.gov. December 2012. Archived from the original on 19 December 2016.

Field SK (July 2015). “Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?”.Therapeutic Advances in Chronic Disease. 6 (4): 170–84. Doi:10.1177/2040622315582325.

“Prescribing Information for Bedaquiline” (PDF). Archived (PDF) from the original on 24 August 2013. Retrieved 28 April 2014.

Centers for Disease Control Prevention (October 2013). “Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis”.MMWR.Recommendations and Reports. 62 (RR-09): 1–12.

Worley MV, Estrada SJ (November 2014). “Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis”. Pharmacotherapy. 34 (11): 1187–97. Doi:10.1002/phar.1482.

Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D (February 2014). “Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism”. Nature Communications. 5 (1): 3369. Bibcode:2014NatCo...5.3369K. doi:10.1038/ncomms4369.

Andries K Verhasselt P Guillemont Jet al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosisScience20053072237.

Rustomjee R Diacon AH Allen Jet al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosisAntimicrob Agents Chemother20085228315. 17.Diacon AH Pym A Grobusch Met al. The diarylquinoline TMC207 for multidrug-resistant tuberculosisN Engl J Med20093602397405. 18.Janssen Research and DevelopmentAnti-Infective Drugs Advisory Committee Meeting Briefing Document. TMC207 (Bedaquiline): Treatment of Patients With MDR-TB. NDA 204-384. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf (25 September 2013, date last accessed).

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Diacon AH, Donald PR, Pym A, et al. Antimicrob Agents Chemother. 2012;56:3271–3276.

Drugs.com: Sirturo Side Effects Archived 2013-09-23 at the Wayback Machine.

https://www.1mg.com/generics/bedaquiline-405152wpsrc=Google+Organic+Search.Retrieved on 26 Jun 2023. 22. “Linezolid”. The American Society of Health-System Pharmacists.Archived from the original on 20 December 2016.Retrieved 8 December 2016.

Zyvox- linezolid injection, solution Zyvox- linezolid tablet, film coated Zyvox- linezolid suspension”. DailyMed. 21 February 2020. Retrieved 17 March 2020.

Herrmann DJ, Peppard WJ, Ledeboer NA, Theesfeld ML, Weigelt JA, Buechel BJ (December 2008). “Linezolid for the treatment of drug-resistant infections”.Expert Review of Anti-infective Therapy. 6 (6): 825–48. Doi:10.1586/14787210.6.6.825.

Brickner SJ (1996). “Oxazolidinone antibacterial agents”.Current Pharmaceutical Design. 2 (2): 175–94. Doi:10.2174/1381612802666220921173820. S2CID 252456453.Detailed review of the discovery and development of the whole oxazolidinone class, including information on synthesis and structure-activity relationships.

Xu GY, Zhou Y, Xu MC (2006). “A convenient synthesis of antibacterial linezolid from (S)-glyceraldehyde acetonide” (PDF).Chinese Chemical Letters. 17 (3): 302–4. Archived from the original (PDF) on 7 July 2011.

Diekema DI, Jones RN. Oxazolidinones: a review. Drugs. 2000 Jan;59(1):7-16.

Antal EJ, Hendershot PE, Batts DH, Sheu WP, Hopkins NK, Donaldson KM. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol. 2001 May;41(5):552-62.

FDA Approved Drug Products: Zyvox (linezolid) for intravenous or oral administration [Link].see old doc ref -link... Podanum. 30.Welshman IR, Stalker DJ, Wajsczuk CP. Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid, Anti-Infect Drugs Chemother, 1998, vol. 16 Suppl 1pg. 54.

Pharmacia Zyvox (linezolid) Clinical Information Pack (Jan. 2001)Peapack, NJ, USAPharmacia.

Lexi-Comp (August 2008). “Linezolid”.The Merck Manual Professional.Archived from the original on 26 April 2009.Retrieved on 14 May 2009.

Wroe D (28 February 2002). “An antibiotic to fight immune bugs”.The Age.Archived from the original on 27 January 2010.Retrieved 16 May 2009.

Wilson AP, Cepeda JA, Hayman S, Whitehouse T, Singer M, Bellingan G (August 2006). “In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients”.The Journal of Antimicrobial Chemotherapy. 58 (2): 470–3. Doi:10.1093/jac/dkl233

Bozdogan B, Appelbaum PC (February 2004). “Oxazolidinones: activity, mode of action, and mechanism of resistance”. International Journal of Antimicrobial Agents. 23 (2): 113–9. Doi:10.1016/j.ijantimicag.2003.11.003.

”FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs”U.S. Food and Drug Administration FDA) (Press release). 14 August 2019. Retrieved 28 August 2019.Public Domain.

”Drug Trials Snapshots: Pretomanid”Food and Drug Administration(FDA). 14 August 2019. Retrieved 17 March 2020. 38.”PA-824 has a New Generic Name: Pretomanid”TB Alliance. Retrieved 18 April 2019.

Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM (June 2005). “Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models”.Antimicrobial Agents and Chemotherapy. 49 (6): 2294–301. Doi:10.1128/AAC.49.6.2294-2301.2005.

Pretomanid FDA label, August 2019 [Link].

Thompson AM, Bonnet M, Lee HH, Franzblau SG, Wan B, Wong GS, Cooper CB, Denny WA: Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid. ACS Med Chem Lett. 2017 Nov 13;8(12):1275-1280. Doi: 10.1021/acsmedchemlett.7b00356. eCollection 2017 Dec 14.

TB Alliance presentation slides [Link].

Lyons MA: Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. Antimicrob Agents Chemother. 2018 Jun 26;62(7). Pii: AAC.02359-17. Doi: 10.1128/AAC.02359-17. Print 2018 Jul. 44.https://www.drugs.com/mtm/pretomanid.html#google-vignetteRetrieved on 1Jul 2023 45.https://medlineplus.gov/druginfo/meds/a619056.html#:~:text=Pretomanid%20is%20used%20along%20with,class%20of%20medications%20called%20antimycobacterials.Retrieved on 2Jul 2023. 46.Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD: Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013 Jun;41(6):1393-400. Doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.

World Health Organization (2015). The selection and use of essential medicines.Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. Pp. 30–1. Hdl:10665/189763. ISBN 9789241209946.ISSN 0512-3054. WHO technical report series;994. 48.Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions Elsevier. 2016. P. 284. ISBN 9780444638892.Archived from the original on 2016-12-20. 49.Pharmazeutischezeitung:Delamanid: Neuer Wirkstoff gegen multiresistente TB Archived 2015-09-24 at the Wayback Machine, 9 May 2014. (in German).

Deltyba, INN-Delamanid – European Medicines Agency – Europa EU [Link]

Lewis JM, Sloan DJ: The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag. 2015 May 13;11:779-91. Doi: 10.2147/TCRM.S71076. eCollection 2015. 52.AlphienesStanley Xavier, Mageshwaran Lakshmanan.Delamanid: A new armor in combating drug-resistant tuberculosis.J pharmacol pharmacother. 2014 Jul – sep ;5( 3): 222-224. Doi: 10.4130/ 0976 - 500X. 136121.

Lewis JM, Sloan DJ: The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag. 2015 May 13;11:779-91. doi: 10.2147/TCRM.S71076.

Deltyba, INN-Delamanid - European Medicines Agency - Europa EU [Link].

Katsunori Sasahara, Yoshihiko Shimokawa, Yukihiro Hirao, Noriyuki Koyama, Kazuyoshi Kitano, Masakazu Shibata and Ken Umehara.Pharmacokinetics and Metabolism of Delamanid, a Novel Anti-Tuberculosis Drug, in Animals and Humans: Importance of Albumin Metabolism In Vivo.Drug Metabolism and Disposition.2015, 43 (8) 1267-1276. DOI: 10.1124/dmd.115.064527. 56.https://www.medindia.net/drugs/medication-side-effects/delamanid.htm. Retrieved on :7 Jul 2023.

https://www.1mg.com/generics/delamanid-405151. Retrieved on:7 Jul 2023.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: A Journal of Drug Design & Discovery